SCHEMBL1002853

SCHEMBL1002853

CCCCc1ccccc1C(N)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
CYP3A4 P08684 2/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 2/20 0.53
MEN1 O00255 1/20 0.53
NR1I2 O75469 1/20 0.53
CHRM2 P08172 1/20 0.53
ADRA2A P08913 1/20 0.53
OPRK1 P41145 1/20 0.53
HTR2B P41595 1/20 0.53
SLC6A3 Q01959 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
TSHR P16473 5/20 0.44
LIPG Q9Y5X9 1/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 3/20 0.44
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4760758 0.98 MAPT (0.51) MAPTCYP3A4KMT2ALMNAMEN1
Hydrochloric Acid SCHEMBL15954597 0.98 MAPT (0.51) MAPTCYP3A4KMT2ALMNAMEN1
Benzene SCHEMBL28299279 0.98 KMT2A (0.51) MAPTCYP3A4KMT2ALMNAMEN1
SCHEMBL1004433 0.95 CYP3A4 (0.55) MAPTCYP3A4KMT2ALMNAMEN1
SCHEMBL1004554 0.93 LMNA (0.58) MAPTCYP3A4KMT2ALMNAMEN1
SCHEMBL421013 0.93 LMNA (0.58) MAPTCYP3A4KMT2ALMNAMEN1
SCHEMBL1002777 0.93 LMNA (0.58) MAPTCYP3A4KMT2ALMNAMEN1
SCHEMBL1003944 0.93 LMNA (0.58) MAPTCYP3A4KMT2ALMNAMEN1
SCHEMBL1004461 0.93 LMNA (0.58) MAPTCYP3A4KMT2ALMNAMEN1
SCHEMBL5566506 0.93 LMNA (0.58) MAPTCYP3A4KMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118221554-A Method for preparing antibacterial agent 2, 2-dithio-bis (n-butylbenzamide) 常州大学 2024-06-21 CN claimed
JP-2011524867-A 2011-09-08 JP claimed
CN-102060857-A Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA SPA 2011-05-18 CN claimed
EP-2300472-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2011-03-30 EP claimed
EP-2271646-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-01-12 EP claimed
WO-2009149139-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-10 WO claimed
WO-2009123986-A1 APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-08 WO claimed
WO-2009077608-A1 2 -AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 ANTAGONISTS PALAU PHARMA, S. A. (ES) 2009-06-25 WO claimed
CN-101223141-A Certain substituted amides, method of making, and method of use thereof CGI PHARMACEUTICALS INC (US) 2008-07-16 CN claimed
CN-101208306-A Pyrazole compounds and diabetes therapeutic agent containing the same JAPAN TOBACCO INC (JP) 2008-06-25 CN claimed
CN-101115710-A Diamine calcium channel blockers NEUROMED PHARMACEUTICALS LTD (CA) 2008-01-30 CN claimed
CN-100354276-C Biologically active compounds AMURA THERAPEUTICS LTD (GB) 2007-12-12 CN claimed
CN-1993331-A N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer CHIRON CORP (US) 2007-07-04 CN claimed
CN-1681817-A Biologically active compounds AMURA THERAPEUTICS LTD (GB) 2005-10-12 CN claimed
CN-1447810-A Bicyclic pyrazoles with kinase inhibitor activity, process for their preparation and pharmaceutical compositions containing them PHARMACIA ITALIA SPA (IT) 2003-10-08 CN claimed
US-12415822-B2 Small molecule inhibitors selective for polo-like kinase protein UNIVERSITY OF SOUTH CAROLINA (US) 2025-09-16 US disclosed
CN-118290448-A Mixed amide zinc-oxygen alkane complex and preparation method and application thereof 江苏爱姆欧光电材料有限公司 2024-07-05 CN disclosed
EP-0323887-A2 Heat-sensitive diazo recording materials FUJI PHOTO FILM CO., LTD. (JP) 1989-07-12 EP disclosed
US-4792628-A ANTIOXIDANTS, ANTIINFLAMMATORY AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-12-20 US disclosed
US-3982931-A N,N-di-sec.butyl-benzamide herbicides MONTEDISON S.P.A. (IT) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415822-B2 Small molecule inhibitors selective for polo-like kinase protein PLK2, PLK4, PLK3 MAPT 1446/4885CYP3A4 4617/4885KMT2A 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.